Clinical trials: Refractory Acute Leukemia
B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT06533579
- Testing
- Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Vironexis Biotherapeutics Inc.
Brain and Central Nervous System Tumors, Leukemia
Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of liposomal cytarabine in treating young patients who have…
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00003073
- Testing
- liposomal cytarabine
- Where
- 6 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Leukemia, Lymphoma
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Tretinoin may help hematologic cancer cells develop into normal white blood cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006220
- Testing
- arsenic trioxide, tretinoin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukaemia, Myelodysplasia
Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)
This study has been designed to investigate the safety and feasibility of using a chemotherapy drug, Clofarabine, to reduce the disease burden before a donor transplant, in patients with high risk Acute Myeloid Leukaemia or…
- Trial name
- NCT01422603
- Testing
- Clofarabine
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
B-cell Lymphoma, Acute Myeloid Leukemia
A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
Evaluation of the safety, tolerability, pharmacokinetics, and preliminary efficacy of XS-04 in patients with relapsed or refractory hematologic malignancies
- Conditions
- B-cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT06820268
- Testing
- XS-04 tablet
- Where
- 4 sites in China
- Volunteers
- 168 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
This phase I trial studies the best dose and side effects of the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and combinations of ipilimumab, nivolumab, and cemiplimab in treating patients with multiple myeloma, acute…
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome
- Trial name
- NCT03017820
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- Mayo Clinic
Acute Myeloid Leukemia
LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy
This research study is evaluating a targeted therapy as a possible treatment for acute myeloid leukemia (AML) that has returned or not responded to standard treatment.
- Trial name
- NCT04081259
- Testing
- LY3214996
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Dana-Farber Cancer Institute
B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route…
- Trial name
- NCT05397496
- Testing
- PIT565
- Where
- 18 sites in United States, Belgium and 7 more
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myeloid, Leukemia
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
This study is to evaluate the safety and preliminary efficacy of adding the PI3K-gamma inhibitor, eganelisib, to a standard of care treatment option with combination venetoclax and azacitidine in participants with acute myeloid…
- Conditions
- Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia, Refractory Leukemia
- Trial name
- GAVEL (NCT07439211)
- Testing
- Eganelisib, Azacitidine, Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Jacqueline Garcia, MD
B-cell Acute Lymphoblastic Leukemia
Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL
Hypotheses: The Investigator hypothesizes that targeting ALL cells with 2 different modalities, ie liposomal vincristine sulfate as a microtubule inhibitor and blinatumomab as a BITE immuno-oncology therapy, will have at least…
- Trial name
- NCT04448834
- Testing
- Blinatumomab
- Where
- 3 sites in United States
- Sponsor
- Dorothy Sipkins, MD, PhD
ALL, Adult, AML, Adult
A Study of BN104 in the Treatment of Acute Leukemia
The Phase I/II trial is to learn the safety, pharmacokinetics, and preliminary efficacy of BN104 taken once daily or twice daily in patients with acute lymphocytic leukemia or acute myeloblastic leukemia.
- Conditions
- ALL, Adult, AML, Adult, Acute Leukaemia, KMT2A Rearrangement
- Trial name
- NCT06052813
- Testing
- BN104 monotherapy, BN104 monotherapy - rp2d
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Institut de Recherches Internationales Servier (I.R.I.S.)
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
The goal of this research study is to find the safest and most effective dose of the study drug, BXCL701, for the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).
- Trial name
- NCT05703542
- Testing
- BXCL701
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Eric Stephen Winer, MD
B-cell Acute Lymphoblastic Leukemia
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Researchers are looking for new ways to treat people with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) that is CD19 positive using a medicine called MK-1045.
- Trial name
- NCT07570173
- Testing
- MK-1045, Blinatumomab, Acetaminophen
- Where
- 27 sites in Canada, Denmark and 8 more
- Volunteers
- 340 people
- Sponsor
- Merck Sharp & Dohme LLC
B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors.
- Conditions
- B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, Multiple Myeloma
- Trial name
- NCT07239323
- Testing
- Invivo CAR-T
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
This phase Ib trial studies the side effects and best dose of pembrolizumab and how well it works in combination with decitabine with or without venetoclax in treating patients with acute myeloid leukemia or myelodysplastic…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
- Trial name
- NCT03969446
- Testing
- Decitabine, Pembrolizumab, Venetoclax
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- City of Hope Medical Center
Refractory Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia
Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML
This is a Phase I open-label dose escalation study of a single infusion of FATE-NK100 and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting chemotherapy (CY/FLU) in subjects with refractory or…
- Trial name
- NCT03081780
- Testing
- FATE-NK100
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia
A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia
This is an open label, multi-center, phase 1 study of DSP-2033 (Alvocidib) in combination with cytarabine/mitoxantrone (ACM regimen) or cytarabine/daunorubicin (A+7+3 regimen) in patients with acute myeloid leukemia (AML).
- Trial name
- AML (NCT03563560)
- Testing
- Alvocidib, Cytarabine, Mitoxantrone
- Where
- 11 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
This randomized phase I trial is studying the side effects and best dose of vorinostat when given together with idarubicin in treating patients with relapsed or refractory leukemia or myelodysplastic syndromes.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00331513
- Testing
- vorinostat, idarubicin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
To assess the impact of moderate hepatic impairment on cytarabine and daunorubicin pharmacokinetics and their metabolites following administration of CPX-351.
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
- Trial name
- NCT02269579
- Testing
- CPX-351
- Where
- 5 sites in United States
- Sponsor
- Jazz Pharmaceuticals
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
This phase II trial studies how well giving fludarabine phosphate, cyclophosphamide, tacrolimus, mycophenolate mofetil and total-body irradiation together with a donor bone marrow transplant works in treating patients with…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00049504
- Testing
- cyclophosphamide, fludarabine phosphate, tacrolimus
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center